Weight
Cagrilintide
Metabolic
38
Amino acids
Molecular weight
Peptide
Type
Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes. Phase 3 trials demonstrate 22.7% weight loss with CagriSema combination.
Top researched benefits
Overview of Cagrilintide
Subcutaneous injection enables optimal bioavailability, targeting dual amylin and calcitonin receptors for satiety and metabolic regulation. Enhances insulin sensitivity and controls gastric emptying.
Weight Loss
- Phase 3 trials demonstrate significant weight loss.
- 22.7% weight loss with CagriSema combination, surpassing existing therapies.
- 15.7% weight loss in diabetic patients with concurrent glycemic improvements.
Metabolic
- 2.2% HbA1c reduction with CagriSema versus semaglutide alone.
- Amylin receptor activation enhances insulin sensitivity and glucose metabolism.
Appetite Control
- Dual pathway satiety via amylin and calcitonin receptor activation.
Storage
Lyophilized: -20°C frozen; Reconstituted: 2-8°C refrigerated, use within 30 days
Frequency
Once weekly, same day each week
Typical Dose
2.4mg weekly (after escalation)
Cycle Duration
Continuous long-term therapy
Chemical Makeup
Key benefits
FDA development candidate with extensive Phase 3 data
Superior weight loss in combination with semaglutide (22.7%)
Once-weekly convenience
2.2% HbA1c reduction with CagriSema
Community interest
This peptide is still gaining traction in the community.
Long-Acting Amylin Receptor Agonist | Weight Loss & Diabetes
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesCagrilintide Molecular Information
View the scientifc details of Cagrilintide.
38
Amino Acids
Cagrilintide
?
?
Position 1
Lys
Lys
Position 2
Cys
Cys
Position 3
Asn
Asn
Position 4
Thr
Thr
Position 5
Ala
Ala
Position 6
Thr
Thr
Position 7
Cys
Cys
Position 8
Ala
Ala
Position 9
Thr
Thr
Position 10
Gln
Gln
Position 11
Arg
Arg
Position 12
Leu
Leu
Position 13
Ala
Ala
Position 14
Glu
Glu
Position 15
Phe
Phe
Position 16
Leu
Leu
Position 17
Arg
Arg
Position 18
His
His
Position 19
Ser
Ser
Position 20
Ser
Ser
Position 21
Asn
Asn
Position 22
Asn
Asn
Position 23
Phe
Phe
Position 24
Gly
Gly
Position 25
Pro
Pro
Position 26
Ile
Ile
Position 27
Leu
Leu
Position 28
Pro
Pro
Position 29
Pro
Pro
Position 30
Thr
Thr
Position 31
Asn
Asn
Position 32
Val
Val
Position 33
Gly
Gly
Position 34
Ser
Ser
Position 35
Asn
Asn
Position 36
Thr
Thr
Position 37
Pro
Pro
Position 38
Molecular Weight
4409DaChain Length
38Amino AcidsType
PeptideCagrilintide Protocols
Subcutaneous injection to abdomen, thigh, or upper arm. Pre-filled pen design when commercially available.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| Weight Loss (Monotherapy) | 2.4 | 1 week range | SubQ |
| Weight Loss (CagriSema) | 2.4 | 1 week range | SubQ |
| Type 2 Diabetes Management | 2.4 | 1 week range | SubQ with metformin |
| Dose Escalation Protocol | 0.25 | 16 week range | SubQ |
Reconstitution Instructions
Materials needed:
Steps to reconstitute
- CRITICAL: Requires acidic pH (3.5-4.5) to prevent fibril formation
- Reconstitute slowly down vial side; swirl gently (do not shake)
- Verify pH 3.5-4.5 after reconstitution
- Solution must be clear—discard if cloudy or particulate
- Store refrigerated (2-8°C); inspect before each injection
- Allow 15-30 minutes to reach room temperature before injection
- Rotate injection sites weekly
Cagrilintide Cycle
The Cagrilintide Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
- Week 4-8
- Early weight loss (2-5%); noticeable appetite reduction
- Week 12-26
- Significant weight loss acceleration (10-15%); improved satiety signals
- Week 0-0
- Peak efficacy (15-23% weight loss); sustained maintenance with continued therapy
- Week 1-2
- Gastrointestinal adaptation; mild nausea possible during dose escalation
Dosing tools
Cagrilintide Peptide Dosage Calculator
Calculate peptide doses with our visual syringe guide.
0.3mL / 30 units
5 units
0.050 mL
1 mL
2 mL
3 mL
5 mL
Custom
Conversion: 1,000 mcg = 1 mg
Injection Results
Based on your vial and dilution inputs.
Safe concentration range
Cagrilintide
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg Cagrilintide vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
Research Purposes Only
These calculators are provided for educational and research purposes only. Always verify calculations and consult with qualified professionals. The information provided is not medical advice. Peptides should only be used in accordance with applicable laws and regulations.
Reference Guide
Dosing Cycle
- Peptide
- Cagrilintide
- Dosing
- 2.4mg weekly (after escalation)
- Dosing Frequency
- Once weekly, same day each week
- Cycle Duration
- Continuous long-term therapy
- Storage
- Lyophilized: -20°C frozen; Reconstituted: 2-8°C refrigerated, use within 30 days
Note: Triple agonist; microdose for fewer side effects
Reconstitution Tips
- Use bacteriostatic water (BAC) — contains 0.9% benzyl alcohol for preservation
- Inject water slowly — aim down the vial wall, not directly onto powder
- Never shake — gently swirl or roll the vial until dissolved
- Store properly — refrigerate at 2-8°C after reconstitution
- Use within 28 days — most reconstituted peptides remain stable for about 4 weeks
- Keep sterile — always clean vial tops with alcohol before drawing
Peptide Interactions
Research suggestions of Cagrilintide interactions with other common peptides and substances.
Weight
ret
Metabolic
Retatrutide
MONITOR
Compounded GI side effects create substantial risk without specialist supervision.
Weight
sem
Metabolic
Semaglutide
SYNERGISTIC
CagriSema combination achieves enhanced weight loss through complementary GLP-1 and amylin pathways.
Weight
tir
Metabolic
Tirzepatide
COMPATIBLE
No known direct interactions; different mechanisms allow concurrent use.
Side effects
Monitor: Be careful when combining Cagrilintide with Retatrutide.
Contraindications
Not recommended in pregnancy or breastfeeding
Not yet commercially available (FDA approval expected Q1 2026)
Stop signs
Severe persistent nausea/vomiting preventing hydration
Pancreatitis signs (severe abdominal pain radiating to back)
Severe allergic reactions or anaphylaxis
Significant injection site reactions or abscess formation
Bad signs
Comments
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Frequently asked questions
What benefits can peptides offer in research?
Peptides can support cellular repair, immune function, metabolic health, and tissue regeneration. Research suggests they may help with recovery, sleep quality, skin health, and cognitive function, depending on the specific peptide and its mechanism of action.
What are some exciting applications of peptides in modern science?
Current research explores peptides for longevity, muscle recovery, wound healing, metabolic disorders, and neuroprotection. Scientists are also investigating peptide-based drug delivery and targeted therapies that could offer more precise treatment options.
How do peptides influence health and wellness?
Peptides work by binding to receptors on cells and triggering specific biological responses. Depending on the peptide, they may promote growth hormone release, support collagen production, modulate inflammation, or influence neurotransmitter activity—each with different implications for health and wellness.
Where can I find the latest studies on peptide applications?
Peer-reviewed journals such as Nature, Science, and specialized publications like Peptides and the Journal of Peptide Science publish ongoing research. PubMed and Google Scholar are useful for searching studies by peptide name or condition.
Are there any guidelines for using peptides in research?
Research use of peptides typically follows institutional review board (IRB) protocols and regulatory guidelines. Dosage, administration route, and safety monitoring should align with published literature and applicable regulations in your jurisdiction.
What is the difference between peptides and proteins?
Peptides are short chains of amino acids (typically under 50), while proteins are longer chains that fold into complex structures. Peptides are often more stable, easier to synthesize, and can cross cell membranes more readily, making them attractive for therapeutic applications.
How should peptides be stored?
Most peptides require refrigeration (2–8°C) and protection from light. Reconstituted peptides often have shorter stability and may need to be used within days or weeks. Always follow the manufacturer's or research protocol's storage instructions.
Can peptides be taken orally?
Some peptides are bioavailable orally, but many are broken down by digestive enzymes before reaching the bloodstream. Subcutaneous injection, nasal administration, or other routes are often used in research to improve bioavailability. The optimal route depends on the specific peptide.
CagrilintideResearch References
Cagrilintide is an extensively studied compound
Cagrilintide
Cagrilintide is an extensively studied compound
REDEFINE 1 Trial - Phase 3 Weight Loss
3,417 adults with obesity; 22.7% weight loss with CagriSema vs 2.4% placebo. New England Journal of Medicine.
2025
REDEFINE 2 Trial - Phase 3 Type 2 Diabetes
1,206 adults; 15.7% weight loss; 73.5% achieved HbA1c ≤6.5%. New England Journal of Medicine.
2025
Phase 2 Type 2 Diabetes Combination Study
32 weeks; 15.6% weight loss; 2.2% HbA1c reduction with CagriSema. The Lancet.
2023